Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE AAA Research Reports
LONDON, September 17, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Monday, September 16, 2013, the U.S. equity market ended on a mixed note. The S&P 500 and the Dow Jones Industrial Average gained 0.57% and 0.77% respectively, while the NASDAQ Composite fell by 0.12%. Shares in healthcare- drug makers made advances, even as the broader market fluctuated between gains and losses. The major movers in the industry included Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly & Company (NYSE: LLY), Endo Health Solutions Inc. (NASDAQ: ENDP), and Allergan Inc. (NYSE: AGN). AAAResearchReports.com initiated preliminary technical research on BMY, LLY, ENDP, and AGN. These free reports are accessible by signing today at:
Shares in Bristol-Myers Squibb Co. surged on Monday, extending the gains from the previous trading session. The company's shares finished the day 3.63% higher at $45.14 after trading between $44.37 and $45.42. A total of 10.21 million shares were traded, which is above the daily average volume of 7.36 million. The company's shares have gained 4.35% in the previous three trading sessions and 8.30% in the last one month, outperforming the S&P 500 which has advanced 0.50% and 2.52% during the respective periods. Further, Bristol-Myers Squibb Co.'s stock is trading above its 50-day and 200-day moving averages of $43.33 and $40.15, respectively. The free technical analysis on BMY is available by signing up at:
On Monday, Eli Lilly & Co.'s stock advanced to close at $53.64, up 0.69% from the previous day's closing price of $53.27. The company's shares oscillated between $53.43 and $53.84 during the trading session. A total of 2.67 million shares were traded, which is below the daily average volume of 5.07 million. The company's shares are up 1.59% in the previous three trading sessions and 3.05% in the last three months, compared to a gain of 0.50% and 4.36% in the S&P 500 during the respective periods. Additionally, Eli Lilly & Co.'s stock is trading above its 50-day and 200-day moving averages of $52.41 and $53.11, respectively. Register now to download free research on LLY at:
Shares in Endo Health Solutions Inc. rose marginally on Monday, even as the broader market ended on a mixed note. The company's shares fluctuated between $43.71 and $44.40 before ending the day 0.09% higher at $43.74. A total of 1.40 million shares were traded, which is below the daily average volume of 1.68 million. The company's shares have surged 18.83% in the last one month and 12.79% in the previous three months, outperforming the S&P 500 during both the periods. Moreover, Endo Health Solutions Inc.'s stock is trading near its 52-week high of $44.73 as well as above its 50-day and 200-day moving averages of $39.33 and $33.79, respectively. A free report on ENDP can be accessed by registering at:
Allergan Inc.'s stock rose 0.57% on Monday, extending the gains from the previous trading session. The company's shares closed the day at $89.28, after oscillating between $88.89 and $89.85. A total of 0.99 million shares were traded, which is below the daily average volume of 2.48 million. The company's shares have advanced 1.74% in the previous three trading sessions, compared to a gain of 0.50% in the S&P 500 during the same period. Despite Monday's gain, Allergan Inc.'s stock is trading below its 50-day and 200-day moving averages of $89.87 and $99.56, respectively. Register with AAA Research Reports and download research on AGN for free at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.